CRBUCaribou Biosciences, Inc.

$186M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+8.6% YoY

Gross Profit

$2M71.3% margin

Operating Income

-$29M-1337.6% margin

Net Income

-$28M-1253.3% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-17.6%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$195M

Total Liabilities

$53M

Stockholders' Equity

$142M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	+8.6%
Gross Profit	$2M	$2M	-22.6%
Operating Income	-$29M	-$38M	+23.1%
Net Income	-$28M	-$35M	+20.6%

Revenue Segments

Reportable Segment

$2M100%

Geographic Segments

UNITED STATES

$2M83%

Non-US

$377,00017%

CRBU Q3 2025 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena